"Benzazepines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with BENZENE fused to AZEPINES.
| Descriptor ID |
D001552
|
| MeSH Number(s) |
D03.633.100.079
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzazepines".
Below are MeSH descriptors whose meaning is more specific than "Benzazepines".
This graph shows the total number of publications written about "Benzazepines" by people in this website by year, and whether "Benzazepines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 5 | 1 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2016 | 3 | 0 | 3 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzazepines" by people in Profiles.
-
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. Eur J Heart Fail. 2020 01; 22(1):164-167.
-
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
-
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
-
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
-
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
-
Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob Res. 2014 Dec; 16(12):1638-46.
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
-
Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. JAMA Intern Med. 2013 May 13; 173(9):817-9.
-
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
-
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb; 165(2):216-25.